GlobeNewswire Inc.··Pomerantz LlpMereo BioPharma Stock Collapses 88% on Failed Trials; Class Action Lawsuit Filed
Pomerantz Law Firm files securities fraud lawsuit against $MREO after failed Phase 3 trials tank stock 87.7%. Lead Plaintiff deadline: April 6, 2026.
MREORAREsecurities fraudclass action lawsuit